Panitumumab (PAN) vs bevacizumab (BEV) in metastatic colorectal cancer (mCRC) by microsatellite stable (MSS), RAS/BRAF, and HER2 amplification (HER2amp) status: Phase III PARADIGM biomarker study-MedSci.cn

Panitumumab (PAN) vs bevacizumab (BEV) in metastatic colorectal cancer (mCRC) by microsatellite stable (MSS), RAS/BRAF, and HER2 amplification (HER2amp) status: Phase III PARADIGM biomarker study

Kato, T; Muro, K; Watanabe, J; Shitara, K; Yamazaki, K; Ohori, H; Shiozawa, M; Yasui, H; Oki, E; Sato, T; Naitoh, T; Komatsu, Y; Soeda, J; Yamamoto, K; Yamashita, R; Akagi, K; Ochiai, A; Uetake, H; Tsuchihara, K; Yoshino, T

ANNALS OF ONCOLOGY, 2023; 34 (): S1503

科室
- - 订阅+
  - 更多科室
工具
服务